| 5-FU | Fluorouracil |
| AE | Adverse events |
| ALT | Alanine aminotransferase |
| AST | Aspartate aminotransferase |
| CNTs | concentrative nucleoside transporters |
| CTCAE | Common Terminology Criteria for Adverse Events |
| CR | Complete response |
| ENTs | Equilibrative nucleoside transporters |
| FOLFIRINOX | Chemotherapy regimen containing fluorouracil, folinic acid, irinotecan, and oxaliplatin |
| MMRI | Molecular magnetic resonance imaging |
| NP/G | Nab-paclitaxel plus gemcitabine |
| ORR | Objective response rate |
| OS | Overall survival |
| PDAC | Pancreatic ductal adenocarcinoma |
| PFS | Progression-free survival |
| PR | Partial response |
| PRISMA | Preferred Reporting Items for Systematic Reviews |
| TNBC | Triple-negative breast cancer |
| TNM | Tumor/Node/Metastasis staging system from the American Joint Committee on Cancer |
| UTI | Urinary tract infection |